| New from NCI |
| An Important Moment in Tobacco Control |
 |
|
This blog describes the court-ordered “corrective statements” that the three major US tobacco companies are required to print in newspapers and run on TV during prime time over the next year. |
| Video—Human Papillomavirus (HPV): Did You Know? |
 |
|
Learn about the HPV virus and its relationship to cancer. Find out how it is transmitted, who is most at risk, and the vaccine that can prevent it. |
| Video—The Latest in Research for Advanced Breast Cancer |
 |
|
If you missed the live broadcast, you can now watch the recording of our Facebook Live event. Listen to NCI’s Dr. Stan Lipkowitz and Dr. Alexandra Zimmer discuss the latest research for advanced breast cancer. |
Antioxidants and Cancer Prevention
Antioxidants are substances that may prevent cancer by protecting cells from the damage caused by free radicals. This updated fact sheet summarizes cancer prevention research that has been done on antioxidants. |
| Endometrial Cancer Incidence Rising in the US and Worldwide |
 |
|
Rates of disease vary widely among countries, and this blog post explains where incidence rates are highest and some possible causes for the rise. |
Dasatinib Approved by FDA for Some Children with Chronic Myelogenous Leukemia
The approval is for the treatment of children with chronic myelogenous leukemia whose cancer cells express the Philadelphia chromosome and whose disease is in a relatively early stage.
|
| PDQ Summary Updates |
Late Effects of Treatment for Childhood Cancer
In our PDQ summary on late effects of treatment for childhood cancer, we’ve updated the section about second cancers that may be caused by treatment.
|
| Drug Information Updates |
Dasatinib for Chronic Myelogenous Leukemia (CML) in Children
We’ve updated our drug information summary on dasatinib, which was recently approved by FDA to treat certain children with CML. It was previously approved for use in adults only. |
Brentuximab Vedotin for Lymphoma
Brentuximab vedotin was recently approved by FDA to treat primary cutaneous anaplastic large cell lymphoma and certain types of mycosis fungoides. |
Sunitinib Malate for Use in Renal Cell Carcinoma
Sunitinib malate is now approved as an adjuvant therapy for patients with renal cell carcinoma (RCC) who have a high risk of recurrent cancer. RCC is a type of kidney cancer. |
